LON:HIK - Hikma Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 1,790 -64.50 (-3.48 %)
(As of 11/12/2018 04:00 PM ET)
Previous CloseGBX 1,854.50
Today's RangeGBX 1,779.50 - GBX 1,873
52-Week RangeGBX 814.20 - GBX 2,346
Volume662,572 shs
Average Volume822,138 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products. The Generics segment develops and sells approximately 100 oral and other non-injectable generic products for oncology and pain management, as well as respiratory, nasal spray, suspension, liquid solution, and high-containment areas. The Branded segment develops, manufactures, and markets branded generics and in-licensed products, such as anti-infective products, as well as chronic therapeutic categories comprising cardiovascular, diabetes, CNS, and oncology products. The company also manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Receive HIK News and Ratings via Email

Sign-up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolLON:HIK
Previous Symbol
CUSIPN/A
Phone+44-20-73992760

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees8,500
Outstanding SharesN/A
Market Cap£0.00
OptionableNot Optionable

Hikma Pharmaceuticals (LON:HIK) Frequently Asked Questions

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals declared a dividend on Wednesday, August 15th. Investors of record on Thursday, August 23rd will be paid a dividend of GBX 0.12 per share on Friday, September 21st. This represents a yield of 0.53%. The ex-dividend date of this dividend is Thursday, August 23rd. The official announcement can be seen at this link. View Hikma Pharmaceuticals' Dividend History.

What price target have analysts set for HIK?

7 Wall Street analysts have issued 12 month price targets for Hikma Pharmaceuticals' stock. Their predictions range from GBX 997 to GBX 2,250. On average, they anticipate Hikma Pharmaceuticals' share price to reach GBX 1,551 in the next twelve months. This suggests that the stock has a possible downside of 13.4%. View Analyst Price Targets for Hikma Pharmaceuticals.

What is the consensus analysts' recommendation for Hikma Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Hikma Pharmaceuticals.

Has Hikma Pharmaceuticals been receiving favorable news coverage?

Media stories about HIK stock have trended negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Hikma Pharmaceuticals earned a daily sentiment score of -2.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an effect on the company's share price in the near term.

Who are some of Hikma Pharmaceuticals' key competitors?

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the folowing people:
  • Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 61)
  • Mr. Mazen Samih Taleb Darwazeh, Exec. Vice Chairman, CEO and Pres of MENA & Emerging Markets (Age 60)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 49)
  • Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 46)
  • Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hikma Pharmaceuticals' stock price today?

One share of HIK stock can currently be purchased for approximately GBX 1,790.

What is Hikma Pharmaceuticals' official website?

The official website for Hikma Pharmaceuticals is http://www.hikma.com/.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.


MarketBeat Community Rating for Hikma Pharmaceuticals (LON HIK)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  538 (Vote Outperform)
Underperform Votes:  367 (Vote Underperform)
Total Votes:  905
MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HIK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/12/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel